You are here

AstraZeneca and Takeda to Collaborate on Parkinson’s Disease Treatment

Phase 1 trials of MEDI1341, an alpha-synuclein antibody, will begin by end of 2017

AstraZeneca and Takeda Pharmaceutical Co., Ltd., have announced that they have entered an agreement to jointly develop and commercialize MEDI1341, an alpha-synuclein antibody in development as a potential treatment for Parkinson’s disease (PD).

Alpha-synuclein is an aggregation-prone protein that contributes to the development of PD. This protein is the major constituent of Lewy bodies, which are pathological protein aggregates that accumulate in the nerve cells of patients with PD and appear to spread throughout the nervous system during the progression of the disease. These insights support the development of new PD medicines that seek to remove existing pathological alpha-synuclein aggregates, prevent their formation, or stop them from spreading. Such therapies could potentially prevent or delay the onset of PD, or halt or slow its progression.

MEDI1341 is an antibody that is differentiated by its high affinity, high selectivity, and reduced effector function (lower interaction with the immune system), which has the potential to achieve a better efficacy and safety profile than other alpha-synuclein antibodies. MEDI1341 is due to enter phase 1 clinical trials later this year.

Under the terms of the agreement, AstraZeneca will lead phase 1 development while Takeda will lead future clinical development activities. The companies will share equally future development and commercialization costs for MEDI1341, as well as any future revenues. Takeda will pay AstraZeneca up to $400 million, including initial revenue in 2017, and development and sales milestones thereafter. Additional terms of the agreement are not disclosed.

Source: AstraZeneca; August 29, 2017.

Recent Headlines

Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs